Trials / Active Not Recruiting
Active Not RecruitingNCT01820858
The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma
A Multicenter, Prospective, Randomized Trial of the Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Ding Ma · Academic / Other
- Sex
- Female
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This randomized trial is studying the efficacy and safety of the chemotherapy compared with radiation therapy alone as adjuvant treatment after operation in Patients with high risk and Stage I endometrial carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paclitaxel | 175 mg/m(2), intravenously (IV) |
| DRUG | Paraplatin (Carboplatin Injection) | AUC=5, IV |
| RADIATION | Pelvic Radiation | 45-50 Gy |
| RADIATION | Vaginal Brachytherapy 1 | 5 Gy, 3 times |
| RADIATION | Vaginal brachytherapy 2 | 5 Gy, 2-4 times |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2025-12-01
- Completion
- 2026-12-01
- First posted
- 2013-03-29
- Last updated
- 2024-04-02
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01820858. Inclusion in this directory is not an endorsement.